<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963182</url>
  </required_header>
  <id_info>
    <org_study_id>2013-001275-21</org_study_id>
    <nct_id>NCT01963182</nct_id>
  </id_info>
  <brief_title>Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer</brief_title>
  <acronym>IriGen</acronym>
  <official_title>Phase II Study: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, non randomized multicenter phase II study, will determine the feasibility
      of individualized dose of irinotecan with the UGT1A1 polymorphism, in patients with
      metastatic colorectal cancer treated with FOLFIRI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>severe toxicity (according to NCI-CTC cotation) and response with adapted dose of irinotecan</measure>
    <time_frame>during the treatment (an expected average of 7 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study of the blood concentration (pharmacokinetic) of irinotecan, the SN38 and SN38-G, and bevacizumab</measure>
    <time_frame>during the first 24 hours of the first cure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of treatment efficacy (progression-free survival, duration of response)</measure>
    <time_frame>to progression (1 year)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>First Line Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>irinotecan dose based on genetic polymorphism of UGT1A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>irinotecan dose based on genetic polymorphism of UGT1A1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Colorectal cancer histologically or cytologically proven

          -  Indication of treatment according to the FOLFIRI + / - bevacizumab or cetuximab or
             panitumumab

          -  Age&gt; 18 years

          -  Presence of at least one measurable target by RECIST

          -  Life expectancy&gt; 3 months

          -  Satisfactory biological functions (renal, hepatic and hematologic)

          -  Affiliation to a social security scheme (or be the beneficiary of such a plan) under
             the terms of the Act of August 9, 2004

          -  Patient has signed, after informing the informed consent form

        Exclusion Criteria:

          -  Patients of childbearing age and not using effective contraception during treatment
             and for at least three months after the end of treatment with irinotecan and at least
             six months after the end of treatment with bevacizumab, cetuximab or panitumumab and
             patient pregnant or nursing

          -  Patient with another pathology deemed incompatible with the entry in the protocol

          -  Prior treatment in metastatic

          -  Patients taking antiepileptic

          -  Allergic reaction or intolerance to irinotecan

          -  Heart failure , kidney , bone marrow , liver or respiratory

          -  Higher bilirubin 1.5 times the upper limit of normal

          -  Significant psychiatric or neurological abnormality

          -  Infectious syndrome requiring treatment with antibiotics or antiviral long-term

          -  Patients with chronic inflammatory bowel disease and / or bowel obstruction

          -  Contraindication Association St. John's wort and yellow fever vaccine

          -  Against Heart indication 5-FU

          -  Concurrent treatment with a drug test , participation in a clinical trial within &lt;30
             days

          -  Patient refused to sign the consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé DEVAUD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie THIVAT</last_name>
    <phone>33473278089</phone>
    <email>emilie.thivat@clermont.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique de la Châtaigneraie</name>
      <address>
        <city>Beaumont</city>
        <zip>63110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle VAN PRAAGH, MD</last_name>
      <email>Isabelle.VANPRAAGH@cjp.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle VAN PRAAGH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé DEVAUD, MD</last_name>
      <phone>33473278141</phone>
      <email>Herve.DEVAUD@cjp.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé DEVAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline PETORIN, MD</last_name>
      <phone>33473750508</phone>
      <email>cpetorin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline PETORIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2013</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

